Skip to main content
PMC home page
Gut logoLink to Gut
. 1994 Jan;35(1):15–18. doi: 10.1136/gut.35.1.15

One week's anti-Helicobacter pylori treatment for duodenal ulcer.

R P Logan 1, P A Gummett 1, J J Misiewicz 1, Q N Karim 1, M M Walker 1, J H Baron 1
PMCID: PMC1374624  PMID: 8307442

Abstract

This open study tested whether eradication of Helicobacter pylori (H pylori) heals duodenal ulcers as well as decreasing recurrence. H pylori was detected in patients with endoscopic duodenal ulcers by histology, CLO-test, culture, and 13C-urea breath test (13C-UBT). Tripotassium dicitrato bismuthate (120 mg) and amoxycillin (500 mg) each four times daily, were given for seven days, with 400 mg metronidazole five times a day on days 5-7. The 13C-UBT was repeated immediately after treatment and endoscopy repeated within 21 days. After treatment unhealed ulcers were reinspected one month later and healed ulcers followed up by 13C-UBT alone for 12 months. Of 45 patients, 44 were available for follow up. Mean pretreatment excess delta 13CO2 excretion was 25.6 per mil, which fell to 2.4 per mil immediately after finishing treatment, indicating clearance of H pylori in every patient. At the second endoscopy (median interval 20 days from start of treatment) 33 of 44 (75%) duodenal ulcers had healed. Ten of the remaining 11 duodenal ulcers were smaller and those 10 healed in the next two weeks with no further treatment. Two patients' ulcers that initially healed with clearance of H pylori recurred three weeks later (both had metronidazole resistant H pylori). H pylori was eradicated in 28 of 44 (64%) patients (13C-UBT negative for median follow up 10.2 months). Overall 41 of 43 (93%, 95% confidence intervals 81%-99%) duodenal ulcers were healed at one month. This study suggests that one week of anti-H pylori triple treatment is effective in healing duodenal ulcers.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axon A. R. Duodenal ulcer: the villain unmasked? BMJ. 1991 Apr 20;302(6782):919–921. doi: 10.1136/bmj.302.6782.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cleaning and disinfection of equipment for gastrointestinal flexible endoscopy: interim recommendations of a Working Party of the British Society of Gastroenterology. Gut. 1988 Aug;29(8):1134–1151. doi: 10.1136/gut.29.8.1134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coghlan J. G., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E., Keane C., O'Morain C. Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet. 1987 Nov 14;2(8568):1109–1111. doi: 10.1016/s0140-6736(87)91545-5. [DOI] [PubMed] [Google Scholar]
  4. Cover T. L., Dooley C. P., Blaser M. J. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun. 1990 Mar;58(3):603–610. doi: 10.1128/iai.58.3.603-610.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crabtree J. E., Taylor J. D., Wyatt J. I., Heatley R. V., Shallcross T. M., Tompkins D. S., Rathbone B. J. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet. 1991 Aug 10;338(8763):332–335. doi: 10.1016/0140-6736(91)90477-7. [DOI] [PubMed] [Google Scholar]
  6. Figura N., Guglielmetti P., Rossolini A., Barberi A., Cusi G., Musmanno R. A., Russi M., Quaranta S. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Microbiol. 1989 Jan;27(1):225–226. doi: 10.1128/jcm.27.1.225-226.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Glupczynski Y., Burette A., De Koster E., Nyst J. F., Deltenre M., Cadranel S., Bourdeaux L., De Vos D. Metronidazole resistance in Helicobacter pylori. Lancet. 1990 Apr 21;335(8695):976–977. doi: 10.1016/0140-6736(90)91043-a. [DOI] [PubMed] [Google Scholar]
  8. Glupczynski Y., Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol. 1990 Dec;85(12):1545–1551. [PubMed] [Google Scholar]
  9. Hui W. M., Ho J., Lam S. K. Pathogenetic role of Helicobacter pylori in duodenal ulcer disease. Multivariate analysis of factors affecting relapse. Dig Dis Sci. 1991 Apr;36(4):424–430. doi: 10.1007/BF01298869. [DOI] [PubMed] [Google Scholar]
  10. Hui W. M., Lam S. K., Ho J., Lai C. L., Lok A. S., Ng M. M., Lau W. Y., Branicki F. J. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci. 1991 May;36(5):577–582. doi: 10.1007/BF01297022. [DOI] [PubMed] [Google Scholar]
  11. Lee A. H pylori-initiated ulcerogenesis: look to the host. Lancet. 1993 Jan 30;341(8840):280–281. doi: 10.1016/0140-6736(93)92624-3. [DOI] [PubMed] [Google Scholar]
  12. Lee F. I., Samloff I. M., Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985 Jun 8;1(8441):1299–1302. doi: 10.1016/s0140-6736(85)92793-x. [DOI] [PubMed] [Google Scholar]
  13. Logan R. P., Gummett P. A., Misiewicz J. J., Karim Q. N., Walker M. M., Baron J. H. One week eradication regimen for Helicobacter pylori. Lancet. 1991 Nov 16;338(8777):1249–1252. doi: 10.1016/0140-6736(91)92111-e. [DOI] [PubMed] [Google Scholar]
  14. Logan R. P., Polson R. J., Baron J. H., Misiewicz J. J. Follow-up after anti-Helicobacter pylori treatment. Lancet. 1991 Mar 2;337(8740):562–563. doi: 10.1016/0140-6736(91)91358-2. [DOI] [PubMed] [Google Scholar]
  15. Marshall B. J., Goodwin C. S., Warren J. R., Murray R., Blincow E. D., Blackbourn S. J., Phillips M., Waters T. E., Sanderson C. R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988 Dec 24;2(8626-8627):1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  16. Martin D. F., Hollanders D., May S. J., Ravenscroft M. M., Tweedle D. E., Miller J. P. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet. 1981 Jan 3;1(8210):7–10. doi: 10.1016/s0140-6736(81)90114-8. [DOI] [PubMed] [Google Scholar]
  17. Moshal M. G. The treatment of duodenal ulcers with TDB: a duodenoscopic double-blind cross-over investigation. Postgrad Med J. 1975;51(5 Suppl):suppl 5–5:40. [PubMed] [Google Scholar]
  18. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  19. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  20. Sidebotham R. L., Batten J. J., Li K., Spencer J., Baron J. H. Some effects of tripotassium dicitrato bismuthate on gastric secretion and the mucus barrier. Aliment Pharmacol Ther. 1990 Oct;4(5):535–546. doi: 10.1111/j.1365-2036.1990.tb00500.x. [DOI] [PubMed] [Google Scholar]
  21. Thomas J. M., Misiewicz G. Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer. Clin Gastroenterol. 1984 May;13(2):501–541. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES